Follow the people · Insider
Gary K. Lee
Gary K. Lee files insider transactions with the SEC as a chief scientific officer of Lyell Immunopharma (LYEL). We hold 5 disclosed purchases and sales filed since 14 February 2022, 3 of them in the last 90 days.
- Files forLYEL
- Disclosed buys and sells5 in all, 3 in the last 90 days
- Last disclosure25 August 2026
Positions held
1 post we hold — a term names its own dates; a run of filings only says when they filed- Filed 11 February 2022 — 21 August 2026Chief Scientific Officer · Lyell Immunopharma (LYEL)26 Form 4 lines · source: SEC Form 4
Everything they disclosed
26 entries, newest first — one per disclosure report, one per Form 4 line- ▼ sold on the open market 1,457 shares of Lyell ImmunopharmaSEC Form 425 August 2026Common Stock · traded 21 August 2026 · filed 25 August 2026
- ▼ sold on the open market 131 shares of Lyell ImmunopharmaSEC Form 411 August 2026Common Stock · traded 10 August 2026 · filed 11 August 2026
- ▼ sold on the open market 130 shares of Lyell ImmunopharmaSEC Form 415 June 2026Common Stock · traded 11 May 2026 · filed 15 June 2026
- ▼ sold on the open market 1,671 shares of Lyell ImmunopharmaSEC Form 412 February 2026Common Stock · traded 11 February 2026 · filed 12 February 2026
- ▼ sold on the open market 1,671 shares of Lyell ImmunopharmaSEC Form 412 February 2026Common Stock · traded 11 February 2026 · filed 12 February 2026
- was granted 4,000 shares of Lyell ImmunopharmaSEC Form 411 February 2026Common Stock · traded 9 February 2026 · filed 11 February 2026
- ▼ sold on the open market 147 shares of Lyell ImmunopharmaSEC Form 411 February 2026Common Stock · traded 10 February 2026 · filed 11 February 2026
- was granted 50,000 shares of Lyell Immunopharma (a derivative holding)SEC Form 411 February 2026Option (right to buy) · traded 10 February 2026 · filed 11 February 2026
- was granted 50,000 shares of Lyell Immunopharma (a derivative holding)SEC Form 411 February 2026Option (right to buy) · traded 10 February 2026 · filed 11 February 2026
- was granted 4,000 shares of Lyell ImmunopharmaSEC Form 411 February 2026Common Stock · traded 9 February 2026 · filed 11 February 2026
- ▼ sold on the open market 147 shares of Lyell ImmunopharmaSEC Form 411 February 2026Common Stock · traded 10 February 2026 · filed 11 February 2026
- ▼ sold on the open market 138 shares of Lyell ImmunopharmaSEC Form 412 November 2025Common Stock · traded 10 November 2025 · filed 12 November 2025
- was granted 68,000 shares of Lyell Immunopharma (a derivative holding)SEC Form 429 October 2025Option (right to buy) · traded 27 October 2025 · filed 29 October 2025
- was granted 8,000 shares of Lyell ImmunopharmaSEC Form 422 August 2025Common Stock · traded 20 August 2025 · filed 22 August 2025
- ▼ sold on the open market 1,453 shares of Lyell ImmunopharmaSEC Form 422 August 2025Common Stock · traded 21 August 2025 · filed 22 August 2025
- ▼ sold on the open market 131 shares of Lyell ImmunopharmaSEC Form 413 August 2025Common Stock · traded 11 August 2025 · filed 13 August 2025
- ▼ sold on the open market 136 shares of Lyell ImmunopharmaSEC Form 413 August 2025Common Stock · traded 12 August 2025 · filed 13 August 2025
- was granted 450,000 shares of Lyell Immunopharma (a derivative holding)SEC Form 426 February 2025Option (right to buy) · traded 10 February 2025 · filed 26 February 2025
- was granted 56,250 shares of Lyell Immunopharma (a derivative holding)SEC Form 426 February 2025Option (right to buy) · traded 10 February 2025 · filed 26 February 2025
- was granted 112,500 shares of Lyell ImmunopharmaSEC Form 426 February 2025Common Stock · traded 10 February 2025 · filed 26 February 2025
- was granted 400,000 shares of Lyell Immunopharma (a derivative holding)SEC Form 413 February 2024Stock Option (right to buy) · traded 9 February 2024 · filed 13 February 2024
- was granted 40,000 shares of Lyell ImmunopharmaSEC Form 413 February 2024Common Stock · traded 9 February 2024 · filed 13 February 2024
- was granted 800,000 shares of Lyell Immunopharma (a derivative holding)SEC Form 420 November 2023Stock Option (right to buy) · traded 16 November 2023 · filed 20 November 2023
- returned to the issuer 800,000 shares of Lyell Immunopharma (a derivative holding)SEC Form 420 November 2023Stock Option (right to buy) · traded 16 November 2023 · filed 20 November 2023
- was granted 600,000 shares of Lyell Immunopharma (a derivative holding)SEC Form 428 February 2023Option (right to buy) · traded 24 February 2023 · filed 28 February 2023
- was granted 800,000 shares of Lyell Immunopharma (a derivative holding)SEC Form 414 February 2022Option (right to buy) · traded 11 February 2022 · filed 14 February 2022
Positions come from the unitedstates/congress-legislators roster, the Office of Government Ethics and the SEC’s Form 4 index. Every disclosed line names its own source and links the document the government published; we print what the filing says and never a price we did not read from it. Headlines and links come from the GDELT Global Knowledge Graph — the story stays with the publisher. The portrait, where we have one, is the public-domain Congressional Bioguide photograph.